G. Wilkinson

Pharmacology · 2001–2006

A researcher in the Science corpus: 4 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom G. Wilkinson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Richard M. Weinshilboum
  2. C. Lenfant

Who trusts G. Wilkinson overall

  1. Shufeng Zhou
  2. Magnus Ingelman-Sundberg
  3. Rolf Backofen

Papers from G. Wilkinson's perspective

Ordered by how strongly the researchers G. Wilkinson trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). (Journal of the American Medical Association (JAMA))
  2. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. (American Journal of Respiratory and Critical Care Medicine)
  3. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. (Critical Care Medicine)
  4. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). (Journal of the American Medical Association (JAMA))
  5. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. (Journal of the American Medical Association (JAMA))
  6. Delirium in an intensive care unit: a study of risk factors (Intensive Care Medicine)
  7. Costs associated with delirium in mechanically ventilated patients* (Critical Care Medicine)
  8. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. (Proceedings of the National Academy of Sciences of the United States of America)
  9. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients (AIDS (London))
  10. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6… (Journal of Pharmacology and Experimental Therapeutics)

Their papers